Key result
Robust coronary collaterals linked to an absolute ~7-point reduction in major cardiac events.
Why the study?
The link between good coronary collateral supply and fewer future cardiac ischemic events has not been prospectively established beyond doubt.
Does well-developed coronary collateral flow reduce adverse cardiac ischemic events in patients with stable angina pectoris undergoing PTCA?
Cohort (n=403)
Does well-developed coronary collateral flow reduce adverse cardiac ischemic events in patients with stable angina pectoris undergoing PTCA?
Absolute Event Rate: 2.2% vs 9%
p-value: p=0.01
In patients with stable coronary artery disease, well-developed coronary collateral vessels are associated with a significantly reduced risk of future major cardiac ischemic events.
OBJECTIVES: We sought to evaluate whether coronary collateral flow is clinically relevant for future cardiac ischemic events. BACKGROUND: The link between good collateral supply related to less myocardial damage and fewer cardiac events has not been established prospectively beyond doubt. METHODS: In 403 patients with stable angina pectoris undergoing percutaneous transluminal coronary angioplasty (PTCA) and quantitative collateral assessment, the occurrence of major adverse cardiac events ([MACE] cardiac death, myocardial infarction, unstable angina pectoris) and stable angina pectoris was monitored during follow-up. Collateral flow index (CFI) was determined using intracoronary pressure or Doppler guidewires. Mean aortic ([P(ao)] mm Hg) and distal coronary artery occlusive pressure ([P(occl)] mm Hg) during balloon angioplasty (PTCA), or distal coronary flow velocity time integral during ([V(occl)] cm) and after ([V(ø-occl)] cm) PTCA were measured continuously. Pressure-derived CFI was calculated as follows: (P(occl) - 5)/(P(ao) - 5). Doppler-derived CFI: V(occl)/V(ø-occl). Patients were subdivided into a group with well (CFI > or = 0.25) and poorly developed collaterals (CFI < 0.25). RESULTS: Average follow-up was 94 +/- 56 (15 to 202) weeks. There were 134 patients with CFI >or =0.25 (61 +/- 11 years) and 269 with CFI <0.25 (61 +/- 10 years). The overall cardiac ischemic event rate (MACE and stable angina pectoris) during follow-up was 23% in patients with CFI > or =0.25 and 20% in patients with CFI <0.25 (p = NS). However, only 2.2% of patients with good collateral flow suffered a major cardiac ischemic event, compared with 9.0% among patients with poorly developed collaterals (p = 0.01). The incidence of stable angina pectoris was significantly higher in patients with well developed collaterals than in those with poorly developed collaterals (21% vs. 12%; p = 0.01). CONCLUSIONS: In this relatively large population with chronic stable coronary artery disease undergoing quantitative collateral measurement, the beneficial impact of well developed collateral vessels on the occurrence of future major cardiac ischemic events is clearly demonstrated.
No takes yet. Share an insight, caveat, or question.
Billinger et al. (2002) conducted a cohort in Stable angina pectoris and coronary artery disease (n=403). Well developed coronary collaterals (collateral flow index ≥ 0.25) vs. Poorly developed collaterals (collateral flow index < 0.25) was evaluated on Major adverse cardiac events (cardiac death, myocardial infarction, unstable angina pectoris) (p=0.01). Well-developed coronary collateral flow (index ≥ 0.25) was associated with a significantly lower incidence of major cardiac ischemic events compared to poorly developed collaterals (2.2% vs 9.0%, p=0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: